NewsRx Logo Login/Signup
Home Newsletters Products Library About Us Contact -- Search NewsRx

NewsRx | Free Trials
Advertisement
VerticalNews | Global Warming
NewsRx | Free Newsletters
 
----------
------------
NewsRx on Facebook
-----
NewsRx Passes
Press Release Submissions
PR Login
-----
2008 Award Logo
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
-----
Google 2009 PageRank: #2 Among Top Health News and Media Publications
Google 2009 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2009 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2009 PageRank: #2 News and Media Site for the Pharmaceutical Industry
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

This website is certified by Health On the Net Foundation. Click to verify. This site complies with the HONcode standard for trustworthy health information:
verify here.

Security by Verisign

Telangiectasia


Return to Library

Free Telangiectasia Articles


New epistaxis study findings have been reported by A. Sonijaiswal and co-researchers



2009 AUG 11 - (NewsRx.com) -- According to a study from Manchester, the United Kingdom, "Most patients with hereditary haemorrhagic telangiectasia suffer with frequent episodes of epistaxis. The aim of this case report is to highlight the effect on epistaxis, occurring in hereditary haemorrhagic telangiectasia, when nasal airflow ceases."

"report: We present the interesting case of a patient with hereditary haemorrhagic telangiectasia who experienced cessation of her recurrent, refractory epistaxis through the development of coexisting polyp disease. The patient's enlarged, grade three nasal polyps were behaving as physiological obturators, limiting airflow through her nose. This reduced the intranasal trauma and Subsequent frequency of her nosebleeds. Epistaxis is a debilitating part of hereditary haemorrhagic telangiectasia, and poses a frequent management challenge. Our patient was more tolerant of her grade three nasal polyps than of her recurrent epistaxis," wrote A. Sonijaiswal and colleagues.

The researchers concluded: "This case highlights the importance of reducing nasal airflow when treating patients with hereditary haemorrhagic telangiectasia."

Sonijaiswal and colleagues published their study in the Journal of Laryngology and Otology (A natural obturator in hereditary haemorrhagic telangiectasia. Journal of Laryngology and Otology, 2009;123(6):695-696).

For more information, contact A. Sonijaiswal, Apt 5, 22 Larke Rise, Manchester M20 2UL, Lancs, UK.

Publisher contact information for the Journal of Laryngology and Otology is: Cambridge University Press, Edinburgh Bldg, Shaftesbury Rd., CB2 8RU Cambridge, England.

Keywords: United Kingdom, Manchester, Dermatology, Epistaxis, Laryngology, Nasal Polyps, Otology, Telangiectasia.

This article was prepared by Life Science Weekly editors from staff and other reports. Copyright 2009, Life Science Weekly via NewsRx.com.

NewsRx NewsRx NewsRx
-----------------------
PR Login